▶ AOD-9604 · SUBTOPIC · DOSING LITERATURE

AOD-9604 Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of AOD-9604. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for AOD-9604 reports the following route(s) of administration: Subcutaneous (Phase 2 obesity), Oral (food-supplement contexts in some jurisdictions). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of AOD-9604.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for AOD-9604 of approximately Short (minutes) plasma. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of AOD-9604. Refer to the original publication for full protocol detail.

Heffernan M, et al. (2001) reports the AOD-9604 protocol used in The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice, published in Endocrinology. PMID 11713213. See the source for the protocol-level dose range, frequency, and duration. link
Ng FM, et al. (2000) reports the AOD-9604 protocol used in Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone, published in Horm Res. PMID 11146368. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ What dose was used in trials?

Phase 2 trials used subcutaneous 1 mg/day. This wiki does not recommend any human dose.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · -20 °C 24 months

Reconstituted · 2-8 °C, 28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved as a drug.

WADA · Growth hormone fragments prohibited at all times under S2 on the WADA Prohibited List.

◀ AOD-9604 OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19